Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B.

BACKGROUND Treatment with adefovir dipivoxil for 48 weeks resulted in histologic, virologic, and biochemical improvement in patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B. We evaluated the effect of continued therapy as compared with cessation of therapy. METHODS One hundred eighty-five HBeAg-negative patients with chronic hepatitis B were assigned to receive 10 mg of adefovir dipivoxil or placebo once daily for 48 weeks (ratio, 2:1). After week 48, patients receiving adefovir dipivoxil were again randomly assigned either to receive an additional 48 weeks of the drug or to switch to placebo. Patients originally assigned to placebo were switched to adefovir dipivoxil. Patients treated with adefovir dipivoxil during weeks 49 through 96 were subsequently offered continued therapy. The primary end points were changes in hepatitis B virus (HBV) DNA and alanine aminotransferase levels. RESULTS Treatment with adefovir dipivoxil resulted in a median decrease in serum HBV DNA of 3.47 log copies per milliliter (on a base-10 scale) at 96 weeks and 3.63 log copies per milliliter at 144 weeks. HBV DNA levels were less than 1000 copies per milliliter in 71 percent of patients at week 96 and 79 percent at week 144. In the majority of patients who were switched from adefovir dipivoxil to placebo, the benefit of treatment was lost (median change in HBV DNA levels from baseline, -1.09 log copies per milliliter; only 8 percent of patients had levels below 1000 copies per milliliter at week 96). Side effects during weeks 49 through 144 were similar to those during the initial 48 weeks. Resistance mutations rtN236T and rtA181V were identified in 5.9 percent of patients after 144 weeks. CONCLUSIONS In patients with HBeAg-negative chronic hepatitis B, the benefits achieved from 48 weeks of adefovir dipivoxil were lost when treatment was discontinued. In patients treated for 144 weeks, benefits were maintained, with infrequent emergence of viral resistance.

[1]  Neil Kaplowitz,et al.  Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis , 1981, Hepatology.

[2]  S. Hadziyannis,et al.  Efficacy of long‐term lamivudine monotherapy in patients with hepatitis B e antigen–negative chronic hepatitis B , 2000, Hepatology.

[3]  Pietro Andreone,et al.  Clinical outcome of HBeAg‐negative chronic hepatitis B in relation to virological response to lamivudine , 2004, Hepatology.

[4]  Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group. , 1999 .

[5]  P. Marcellin,et al.  Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. , 2004, The New England journal of medicine.

[6]  A. Lok,et al.  World‐wide epidemiology of HBeAg‐negative chronic hepatitis B and associated precore and core promoter variants , 2002, Journal of viral hepatitis.

[7]  Angeline Bartholomeusz,et al.  Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. , 2003, Gastroenterology.

[8]  A. Makris,et al.  Interferon alfa-2b treatment of HBeAg negative/serum HBV DNA positive chronic active hepatitis type B. , 1990, Journal of hepatology.

[9]  M. Wulfsohn,et al.  Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. , 2003, The New England journal of medicine.

[10]  D. Richman.  The impact of drug resistance on the effectiveness of chemotherapy for chronic hepatitis B , 2000, Hepatology.

[11]  S. Hadziyannis,et al.  The long-term outcome of interferon-α treated and untreated patients with HBeAg-negative chronic hepatitis B , 2001 .

[12]  Brunetto.  Identification of HBV variants which cannot produce pre-core derived HBeAg and may be responsible for severe hepatitis , 1989 .

[13]  A. Lok,et al.  Treatment of hepatitis B , 2002, Journal of Gastroenterology.

[14]  T. Santantonio,et al.  Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine. , 2000, Journal of hepatology.

[15]  M. Wulfsohn,et al.  Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B , 2003, Hepatology.

[16]  D. Vassilopoulos,et al.  Hepatitis B e antigen–negative chronic hepatitis B , 2001, Hepatology.

[17]  A. Morabito,et al.  A randomized, controlled trial of a 24‐month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum , 1997, Hepatology.